Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study

Trial Profile

Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Acute coronary syndromes
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RETAIN
  • Most Recent Events

    • 13 Jul 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
    • 13 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
    • 28 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top